Consistent with previous findings in GBM, hepatocellular carcinoma, and melanoma, our study confirms that elevated LSM2 expression signifies a poor prognosis and it may act as a common oncogenic factor across different cancer types [48–50]. This evidence concerns the gene LSM2 and glioblastoma.